ReviewMolecular biology reports2013
Potential of human γδ T cells for immunotherapy of osteosarcoma.
Review in Molecular biology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis.World journal of gastroenterology · 2014Pooled it
- Identification of a pro-protein synthesis osteosarcoma subtype for predicting prognosis and treatment.Scientific reports · 2024Article
- Integrated analysis of single-cell and bulk RNA sequencing data reveals prognostic characteristics of lysosome-dependent cell death-related genes in osteosarcoma.BMC genomics · 2024Article
- Immunotherapy Innovations in the Fight against Osteosarcoma: Emerging Strategies and Promising Progress.Pharmaceutics · 2024Review
- Classification and function of γδT cells and its research progress in anti-glioblastoma.Discover oncology · 2023Review
- Article
- Data-Driven Mathematical Model of Osteosarcoma.Cancers · 2021Article
- Immune classification of osteosarcoma.Mathematical biosciences and engineering : MBE · 2021Article
- Study on the Killing Effect ofDisease markers · 2021Article
- Overexpression of miR-382 Sensitizes Hepatocellular Carcinoma Cells to γδ T Cells by Inhibiting the Expression of c-FLIP.Molecular therapy oncolytics · 2020Article
- Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS.Molecular medicine reports · 2019Article
- Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.Frontiers in immunology · 2019Review
- Clinical value of Pro-GRP and T lymphocyte subpopulation for the assessment of immune functions of lung cancer patients after DC-CIK biological therapy.Experimental and therapeutic medicine · 2018Article
- Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors.Oncotarget · 2016Article
- Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.Clinical sarcoma research · 2016Article
- T-cell-associated cellular immunotherapy for lung cancer.Journal of cancer research and clinical oncology · 2015Review
- Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.Oncotarget · 2014Article
- γδ T cells for cancer immunotherapy: A systematic review of clinical trials.Oncoimmunology · 2014Review
- B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent or metastatic osteosarcomas remain a challenging malignancy to treat. Therefore, development and testing of novel therapeutic strategies to target these patients are needed. Adoptive cellular therapy strategies are being evaluated intensively as a novel therapeutic strategy for cancer. Unlike αβ T cells requiring antigen processing and MHC-restricted peptide displayed by antigen-presenting cells, γδ T cells exhibit the potent MHC-unrestricted lytic activity against various tumors in vitro and in vivo. The recent considerable success of γδ T cell-based immunotherapy in lung metastasis of renal cell carcinoma warrants further efforts to apply this treatment to other cancers including osteosarcoma, especially recurrent and metastatic osteosarcomas. In this review, we summarize the available evidence on γδ T cell-based immunotherapy for osteosarcoma that has been achieved to date. More importantly, we discuss potential strategies of the combination of expanded γδ T cells and bisphosphonates, and modification and expansion of αβ TCR modified γδ T cells for improving its efficacy for the treatment of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.